Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H5O4.Li |
Molecular Weight | 124.021 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Li+].OC(=O)CCC([O-])=O
InChI
InChIKey=LQNUMILKBSMSMM-UHFFFAOYSA-M
InChI=1S/C4H6O4.Li/c5-3(6)1-2-4(7)8;/h1-2H2,(H,5,6)(H,7,8);/q;+1/p-1
Molecular Formula | C4H5O4 |
Molecular Weight | 117.0801 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Li |
Molecular Weight | 6.941 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/12459525 | http://www.isaltis.com/en/module/99999689/28/lithium_gluconate | https://www.ncbi.nlm.nih.gov/pubmed/18330588https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017812s028,018421s027lbl.pdfCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19538681 | https://www.ncbi.nlm.nih.gov/pubmed/23371914 | http://www.rsc.org/periodic-table/element/3/lithium
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12459525 | http://www.isaltis.com/en/module/99999689/28/lithium_gluconate | https://www.ncbi.nlm.nih.gov/pubmed/18330588https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017812s028,018421s027lbl.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19538681 | https://www.ncbi.nlm.nih.gov/pubmed/23371914 | http://www.rsc.org/periodic-table/element/3/lithium
Lithium is an alkali metal widely used in industry. Lithium salts are indicated in the treatment of manic episodes of Bipolar Disorder. The use of lithium in psychiatry goes back to the mid-19th century. Early work, however, was soon forgotten, and John Cade is credited with reintroducing lithium to psychiatry for mania in 1949. Mogens Schou undertook a randomly controlled trial for mania in 1954, and in the course of that study became curious about lithium as a prophylactic for depressive illness. In 1970, the United States became the 50th country to admit lithium to the marketplace. The specific mechanisms by which lithium exerts its mood-stabilizing effects are not well understood. Lithium appears to preserve or increase the volume of brain structures involved in emotional regulation such as the prefrontal cortex, hippocampus and amygdala, possibly reflecting its neuroprotective effects. At a neuronal level, lithium reduces excitatory (dopamine and glutamate) but increases inhibitory (GABA) neurotransmission; however, these broad effects are underpinned by complex neurotransmitter systems that strive to achieve homeostasis by way of compensatory changes. For example, at an intracellular and molecular level, lithium targets second-messenger systems that further modulate neurotransmission. For instance, the effects of lithium on the adenyl cyclase and phospho-inositide pathways, as well as protein kinase C, may serve to dampen excessive excitatory neurotransmission. In addition to these many putative mechanisms, it has also been proposed that the neuroprotective effects of lithium are key to its therapeutic actions. In this regard, lithium has been shown to reduce the oxidative stress that occurs with multiple episodes of mania and depression. Further, it increases protective proteins such as brain-derived neurotrophic factor and B-cell lymphoma 2, and reduces apoptotic processes through inhibition of glycogen synthase kinase 3 and autophagy.
Originator
Sources: http://www.rsc.org/periodic-table/element/3/lithium
Curator's Comment: The first lithium mineral petalite, LiAlSi4O10, was discovered on the Swedish island of Utö by the Brazilian, Jozé Bonifácio de Andralda e Silva in the 1790s. It was observed to give an intense crimson flame when thrown onto a fire. In 1817, Johan August Arfvedson of Stockholm analysed it and deduced it contained a previously unknown metal, which he called lithium. He realised this was a new alkali metal and a lighter version of sodium. However, unlike sodium he was not able to separate it by electrolysis. In 1821 William Brande obtained a tiny amount this way but not enough on which to make measurements. It was not until 1855 that the German chemist Robert Bunsen and the British chemist Augustus Matthiessen obtained it in bulk by the electrolysis of molten lithium chloride.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24094818 |
6.53 µM [IC50] | ||
Target ID: CHEMBL262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8710892 |
2.0 mM [Ki] | ||
Target ID: O95861 Gene ID: 10380.0 Gene Symbol: BPNT1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10675562 |
0.3 mM [IC50] | ||
Target ID: GO:0038179 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19538689 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LITHIUM CARBONATE Approved UseLithium is indicated in the treatment of manic episodes of Bipolar Disorder. Launch Date-1.26316798E11 |
PubMed
Title | Date | PubMed |
---|---|---|
[Remarkable thymoanaleptic effect of lithium gluconate in recurrent melancholic states]. | 1971 Mar 20 |
|
[Lithium gluconate in emotional disturbances (preliminary results; current orientation)]. | 1971 Oct 20 |
|
[Modifications of serum creatine phosphokinase activity under the influence of lithium gluconate in Duchenne's myopathy]. | 1972 Nov |
|
[Lithium gluconate: systematic and factorial analysis of 104 cases which have been studied for 2 and one-half to 3 years in patients regularly observed and showing periodic cyclothymia or dysthymia]. | 1974 Mar |
|
[Lithium therapy in manic depressive diseases in old age]. | 1975 |
|
The renal pathology in a case of lithium-induced diabetes insipidus. | 1975 Jun |
|
[Treatment of lithium induced polyuria]. | 1975 Mar 10 |
|
Cardiovascular malformations with lithium use during pregnancy. | 1975 May |
|
[Evaluation of the potential cardiotoxicity of propranolol-lithium gluconate association (author's transl)]. | 1980 Mar-Apr |
|
[Ultrastructural modifications in the thyroid glands of mice treated with lithium gluconate]. | 1982 Feb 8 |
|
[Crystalline inclusions of the mouse thyroid. Effect of chronic treatment with lithium gluconate]. | 1986 |
|
Does 'rebound mania' occur after stopping carbamazepine? A pilot study. | 2000 |
|
Regulation of AQP6 mRNA and protein expression in rats in response to altered acid-base or water balance. | 2000 Dec |
|
Glomerular structure in lithium-induced chronic renal failure in rats. | 2000 Oct |
|
The effects of lamotrigine on the pharmacokinetics of lithium. | 2000 Sep |
|
Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline. | 2001 Apr |
|
Ataxia from lithium toxicity successfully treated with high-dose buspirone: a single-case experimental design. | 2001 Aug |
|
Lithium-induced nephrogenic diabetes insipidus in older people. | 2001 Jul |
|
Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells. | 2001 Jul 13 |
|
Lithium-induced exacerbation of stutter. | 2001 Jul-Aug |
|
Bupropion manic induction during euthymia, but not during depression. | 2001 Jun |
|
A historical cohort study of kidney damage in long-term lithium patients: continued surveillance needed. | 2001 Jun |
|
[Nephrotic syndrome and lithium therapy]. | 2001 May 26 |
|
[A case of atropine-resistant bradycardia in a patient on long-term lithium medication]. | 2001 Nov |
|
Tetraspan protein CD151: a common target of mood stabilizing drugs? | 2001 Nov |
|
Synergistic induction of severe hypothermia (poikilothermia) by limbic seizures, acepromazine and physical restraint: role of noradrenergic alpha-1 receptors. | 2001 Oct-Nov |
|
Steroid-induced mania in an adolescent: risk factors and management. | 2001 Summer |
|
Sinus node dysfunction associated with lithium therapy in a child. | 2002 |
|
Lithium-induced tremor treated with vitamin B6: a preliminary case series. | 2002 |
|
[Reversible cardiomyopathy induced by psychotropic drugs: case report and literature overview]. | 2002 Dec |
|
Connection between lithium and muscular incoordination. | 2002 Feb |
|
Intracerebroventricular antisense to inositol monophosphatase-1 reduces enzyme activity but does not affect Li-sensitive behavior. | 2002 Jan |
|
Case report and review of the perinatal implications of maternal lithium use. | 2002 Jul |
|
Lithium induces NF-kappa B activation and interleukin-8 production in human intestinal epithelial cells. | 2002 Mar 8 |
|
Hydroethidine detection of superoxide production during the lithium-pilocarpine model of status epilepticus. | 2002 May |
|
Aminophylline exacerbates status epilepticus-induced neuronal damages in immature rats: a morphological, motor and behavioral study. | 2002 May |
|
Olanzapine-induced mania in bipolar disorders. | 2002 May |
|
[Progressive renal failure caused by lithium nephropathy]. | 2002 May 25 |
|
[Manic state during the addition of lithium in the case of depression resistant to imipramine]. | 2002 Nov 9 |
|
Lithium gluconate in the treatment of seborrhoeic dermatitis: a multicenter, randomised, double-blind study versus placebo. | 2002 Nov-Dec |
|
Risk factors for falls during treatment of late-life depression. | 2002 Oct |
|
Sexual side effects associated with valproate. | 2002 Oct |
|
Status epilepticus induced by lithium-pilocarpine in the immature rat does not change the long-term susceptibility to seizures. | 2002 Sep |
|
Lithium toxicity: a potential interaction with celecoxib. | 2002 Sep-Oct |
|
Reverse pharmacological effect of loop diuretics and altered rBSC1 expression in rats with lithium nephropathy. | 2003 Jan |
|
Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. | 2003 Mar 15 |
|
[Lithium gluconate 8% in the treatment of seborrheic dermatitis]. | 2007 Apr |
|
Anti-inflammatory effects of lithium gluconate on keratinocytes: a possible explanation for efficiency in seborrhoeic dermatitis. | 2008 Jun |
|
Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. | 2017 Apr |
|
Treatment of seborrheic dermatitis: a comprehensive review. | 2019 Mar |
Patents
Sample Use Guides
Optimal patient response to Lithium Carbonate usually can be established and maintained with 600 mg t.i.d. Optimal patient response to Lithium Oral Solution usually can be established and maintained with 10 mL (2 full teaspoons) (16 mEq of lithium) t.i.d. Such doses will normally produce an effective serum lithium level ranging between 1.0 and 1.5 mEq/l. Dosage must be individualized according to serum levels and clinical response. Regular monitoring of the patient’s clinical state and of serum lithium levels is necessary. Serum levels should be determined twice per week during the acute phase, and until the serum level and clinical condition of the patient have been stabilized.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27793772
Although lithium at a high concentration (10 mM) activated β-catenin in different types of neurons, β-catenin shifted to the nucleus at a therapeutically relevant concentration (1 mM) only in thalamic neurons, both in vivo and in vitro.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:43:41 UTC 2023
by
admin
on
Fri Dec 15 17:43:41 UTC 2023
|
Record UNII |
27MNF4VNM5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
25021852
Created by
admin on Fri Dec 15 17:43:41 UTC 2023 , Edited by admin on Fri Dec 15 17:43:41 UTC 2023
|
PRIMARY | |||
|
27MNF4VNM5
Created by
admin on Fri Dec 15 17:43:41 UTC 2023 , Edited by admin on Fri Dec 15 17:43:41 UTC 2023
|
PRIMARY | |||
|
DTXSID90169251
Created by
admin on Fri Dec 15 17:43:41 UTC 2023 , Edited by admin on Fri Dec 15 17:43:41 UTC 2023
|
PRIMARY | |||
|
16090-09-8
Created by
admin on Fri Dec 15 17:43:41 UTC 2023 , Edited by admin on Fri Dec 15 17:43:41 UTC 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
17229-80-0
Created by
admin on Fri Dec 15 17:43:41 UTC 2023 , Edited by admin on Fri Dec 15 17:43:41 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |